Joint Statement On FDA Investigation Of Singulair From The AAAAI And ACAAI
Added: 18 мая 2008
Last relative articles:
- Are You Allergic To Your Home? Proper Spring Cleaning Can Combat Allergens
- Specific Immune Therapy Works For Many People And It Is Becoming Increasingly Popular In Europe
- Morria Biopharmaceuticals Plc Announces Regulatory Approval To Commence Phase II Clinical Study Of MRX-4 In Allergic Rhinitis
- Gluten-Free Bread Mix Sweeps The Board At First Ever Free-From Food Awards, UK
- New Data Demonstrate Efficacy Of Aerius R Desloratadine In Reducing Allergy Symptoms In Patients With Intermittent Allergic Rhinitis
- Treatment Costs Nearly Double For Hay Fever And Other Allergies
- The European Union Funds Researchers From 5 Countries To Test Hygiene Hypothesis
- 12 Million Invested In Improving The Health Of Children Suffering From Asthma And Allergies
- Asthma Rates Soaring Among Adult Hospital Patients, USA
- Stress During Childhood Increases The Risk Of Allergies
Comments: [0] / Post comment:
04 Dec 2008 20:10:45
Merck 2009 profit outlook misses estimates - The Associated Press
Merck 2009 profit outlook misses estimates The Associated Press - ... to be similar to 2008 levels, and slow growth for the asthma and allergy drug Singulair , which was linked this year to reports of suicides. ...
04 Dec 2008 17:38:01
UPDATE: Merck Sees 2009 Profit Below Estimates - CNNMoney.com
Post Chronicle UPDATE: Merck Sees 2009 Profit Below Estimates CNNMoney.com - For Merck , sales unexpectedly slowed this year for top products including the Gardasil cervical-cancer vaccine, the Singulair allergy and asthma treatment, ... Merck issues gloomy 2009 guidance Mercks Lower Profit Forecast Disappoints Investors (Update1) Merck Faces Another Tough Year -04 Dec 2008 16:20:51
Merck Guidance: Ouch - Forbes
Merck Guidance: Ouch Forbes, NY - One big problem: Gardasil, for HPV, and Singulair , for allergies and asthma, will basically show flat growth, executives said on this morning's conference ...
04 Dec 2008 14:03:40
Merck Provides 2009 Financial Guidance; Reaffirms Guidance for ... - MarketWatch
RTT News Merck Provides 2009 Financial Guidance; Reaffirms Guidance for ... MarketWatch - ... Inc.) $23.7 to $24.0 billion Product SINGULAIR (Respiratory) $4.3 to $4.5 billion COZAAR HYZAAR (Hypertension) $3.5 to $3.7 billion FOSAMAX ... Merck & Co., Inc. Guidance Call Transcript03 Dec 2008 22:18:16
Wall Street girds for Merck's 2009 profit forecast - Reuters
Reuters Wall Street girds for Merck's 2009 profit forecast Reuters - The New Jersey-based drugmaker, which is also grappling with flat sales of its Singulair asthma drug, said in October it was cutting 7200 positions, ...02 Dec 2008 06:59:14
Advair's Patient Share In Newly Diagnosed Asthma Patients Declines - eMaxHealth.com
Advair's Patient Share In Newly Diagnosed Asthma Patients Declines eMaxHealth.com, NC - The report also finds that surveyed physicians will continue to use Singulair first-line regardless of March 2008 media reports linking the drug to ...
01 Dec 2008 15:15:35
Advair's Patient Share in Newly Diagnosed Asthma Patients is Declining - International Business Times
Advair's Patient Share in Newly Diagnosed Asthma Patients is Declining International Business Times, NY - The decline in Advair's patient share is due to several factors:physicians' (particularly primary care physicians PCPs ) increasing use ofMerck's Singulair ...
27 Nov 2008 00:52:34
Citigroup analyst cuts target for Merck sales, EPS - Forbes
Citigroup analyst cuts target for Merck sales, EPS Forbes, NY - ... cut his earnings-per-share forecast for the maker of asthma and allergy treatment Singulair and Fosamax for osteoporosis by 2 cents each this year and ...
19 Nov 2008 15:10:18
Merck's 2008: The Year That Wasn't - RTT News
RTT News Merck's 2008: The Year That Wasn't RTT News, NY - In March, Merck's asthma drug Singulair became the subject of FDA investigation, following reports linking the drug to serious adverse side effects like ...18 Nov 2008 01:16:24
Fitch cuts Merck debt outlook to 'Negative' - CNNMoney.com
RTT News Fitch cuts Merck debt outlook to 'Negative' CNNMoney.com - ... from lower-cost generics, and its top selling product, the allergy and asthma drug Singulair , could be vulnerable to generic competition in 2012. ... Fitch Revises Merck & Co.'s Ratings Outlook to Negative Fitch cuts Merck's Ratings Outlook to "Negative" from "Stable"